MBX Biosciences, Inc. Common Stock (MBX) is a publicly traded Healthcare sector company. As of August 19, 2026, MBX trades at $66.51 with a market cap of $3.29B and a P/E ratio of -27.77. MBX moved -2.48% today. Year to date, MBX is +110.91%; over the trailing twelve months it is +356.56%. Its 52-week range spans $4.81 to $72.64. Analyst consensus is strong buy with an average price target of $89.50. Rallies surfaces MBX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks MBX insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $66.51 |
| Market Cap | $3.29B |
| P/E Ratio | -27.77 |
| EPS | $-2.38 |
| Dividend Yield | 0.00% |
| 52-Week High | $72.64 |
| 52-Week Low | $4.81 |
| Volume | 510.04K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-86.97M |
| Gross Margin | 0.00% |
8 analysts cover MBX: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $89.50.